Groundbreaking Research in Singapore

SINGAPORE – In an exciting development that could transform the lives of millions, Singapore will soon be at the forefront of groundbreaking research on the world's first-ever acne vaccine, developed by the French pharmaceutical giant Sanofi.

Memorandum of Understanding

On November 22, Sanofi signed a memorandum of understanding (MOU) with Singapore’s Agency for Science, Technology and Research (A*Star) and the National Skin Centre (NSC) to conduct rigorous research and early-stage clinical trials for the vaccine in patients suffering from mild acne.

Trial Details

This ambitious project aims to recruit around 200 individuals for the trial, which is set to kick off in 2025.

Companion Trials

In the U.S., a related trial for patients with severe acne has already commenced, showcasing Sanofi's commitment to tackling this widespread skin condition.

Potential of the Vaccine

The vaccine aims not only to reduce the severity of acne, which affects approximately 80% of teenagers, but also encourages the possibility of a complete cure.

Holistic Approach to Skin Health

In collaboration with A*Star, Sanofi is poised to delve deeper into understanding skin ailments through expansive research initiatives, aiming at holistic treatment methodologies.

Significance of Singapore's Research

Professor Tan Chorh Chuan, who leads both A*Star and the Ministry of Health’s Office for Healthcare Transformation, emphasized Singapore's unique position to spearhead research tailored to Asian skin conditions.

Understanding Acne

Acne, a chronic inflammatory skin disorder, arises when skin pores become blocked with oil and dead skin cells, and it may afflict individuals well into their 40s or 50s.

Emotional Impact of Acne

The emotional and psychological toll of acne can be significant, impacting self-esteem and leading to issues such as depression.

Hope for Effective Solutions

Dr. Hazel Oon, who heads the NSC’s Acne Clinic, recounted a poignant encounter with a distressed patient struggling with adult acne, underscoring the need for effective solutions.

The Search for a Cure

Addressing the pathology of acne, Dr. Oon expressed hopes that the partnership with Sanofi and A*Star would inch closer to the “Holy Grail” of finding a definitive cure.

Global Prevalence of Acne

Mr. Jean-Francois Toussaint, Sanofi’s global head of vaccine research, highlighted the considerable global prevalence of acne, estimated to affect around 240 million people.

Sanofi's Commitment to Vaccines

Sanofi, renowned for its vaccines – impacting over 500 million individuals annually – ranks sixth globally, with vaccine sales surpassing USD 47 billion in 2023.

Significant Investment in Research

While Mr. Toussaint refrained from revealing the specifics of the investment in the acne vaccine, he assured that the funding is “significant” and part of a broader annual budget of about €7 billion for research in pharmaceuticals and vaccines.

Future Prospects

The forthcoming clinical trial promises not just to generate essential data on acne but also to explore the complexities of skin microbiomes and biological responses in acne progression.

A Global Perspective

With such an extensive collaborative effort, Singapore is not only addressing a local health concern but also paving the way for innovative breakthroughs that can resonate globally.

Conclusion

Stay tuned for what promises to be a potential game-changer in the fight against acne!